Bill
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
119th Congress
Introduced by Rick Allen and 62 co-sponsors
HR 1492 extends drug price negotiations for biologics from 7 to 11 years, aiming to lower costs for consumers and reshape pricing strategies for pharmaceutical companies.
Introduced in House